Welcome to our dedicated page for Vanda Pharma SEC filings (Ticker: VNDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vanda Pharmaceuticals Inc. filings document the company's operating results, commercial product disclosures, regulatory developments, and public-company governance. Form 8-K reports include quarterly and annual financial results, product-related events for NEREUS and BYSANTI, clinical and regulatory forward-looking language, and management communications about commercial strategy.
The company's proxy and governance filings cover director elections, board composition, executive compensation, equity awards, annual bonus and salary decisions, and related stockholder voting matters. Other current reports document board expansion, officer changes, compensatory arrangements, exhibits to press releases, and risk-oriented disclosures tied to Vanda's marketed products and development pipeline.
Vanda Pharmaceuticals Inc. executive Christos Vasilios Mihael Polymeropoulos, Senior VP and Medical Director, filed an initial ownership report showing his equity positions in the company. He holds a stock option to buy 61,200 shares of common stock at an exercise price of $7.05 per share, expiring on February 15, 2033. The filing also lists multiple common stock and restricted stock unit (RSU) awards, with time-based vesting schedules running from March 1, 2027 through March 1, 2029, contingent on his continued employment and delivery of vested shares on the first permissible trading day after each vest date.
Vanda Pharmaceuticals VP and Chief People Officer Howell Scott Laverne filed an initial ownership report showing a mix of stock options, restricted stock units and common shares. His derivative holdings include options covering 77,500 shares at $7.05 per share expiring on February 15, 2033, along with additional grants at higher exercise prices and earlier expiration dates. He also reports multiple direct common stock positions, including one line of 100,000 shares, plus 9,620 shares of common stock held indirectly through a foundation controlled by him and his family members.
Vanda Pharmaceuticals Inc. reported that Timothy Williams has resigned as Senior Vice President, General Counsel and Secretary. He notified the company on March 29, 2026, and his resignation will be effective April 10, 2026, as he plans to pursue other endeavors.
Vanda Pharmaceuticals Inc: The Vanguard Group filed Amendment No. 7 to its Schedule 13G/A reporting that it beneficially owns 0 shares (0%) of Vanda Pharmaceuticals Common Stock following an internal realignment of Vanguard subsidiaries.
The amendment explains certain Vanguard subsidiaries will report separately in reliance on SEC Release No. 34-39538 and states the subsidiaries pursue the same investment strategies previously pursued by The Vanguard Group, Inc. The form is signed by Ashley Grim on 03/27/2026.
Vanda Pharmaceuticals Inc. reported that its President, Chief Executive Officer and Chairman, Dr. Mihael Polymeropoulos, appeared on Fox Business’ Mornings with Maria to discuss pricing and commercial plans for a drug recently approved by the U.S. Food and Drug Administration to prevent vomiting caused by motion.
During the interview, he stated that Vanda is developing a direct-to-consumer channel to provide access to this drug and indicated that the channel is expected to be available in the next couple of months. The company furnished a link to the full televised interview for reference.
Vanda Pharmaceuticals Inc. executive Timothy Williams, its SVP & General Counsel, reported selling 42,434 shares of common stock on March 2, 2026. The shares were sold at a weighted average price of $8.2659 per share solely to satisfy tax obligations arising from the settlement of vested RSUs under the company’s RSU agreements. The transactions occurred in multiple trades at prices ranging from $8.085 to $8.81 per share. After these tax-related sales, Williams directly holds 377,450 shares of Vanda common stock.
Vanda Pharmaceuticals SVP, CFO & Treasurer Kevin Patrick Moran reported an open-market sale of 42,442 shares of common stock on March 2, 2026 at a weighted average price of $8.2659 per share. The filing explains these shares were sold to satisfy tax obligations arising from the settlement of vested RSUs under withholding provisions in the RSU agreements. After the sale, Moran directly held 411,380 common shares and indirectly held 635 additional shares through his wife. The sale occurred in multiple transactions at prices ranging from $8.085 to $8.81 per share.
Vanda Pharmaceuticals Inc. senior vice president and chief marketing officer Joakim Wijkstrom executed an open‑market sale of 30,800 shares of common stock on March 2, 2026 at a weighted average price of $8.2659 per share. The shares were sold to satisfy tax obligations arising from the settlement of vested restricted stock units under the company’s RSU agreements, rather than as a discretionary share sale. After these transactions, Wijkstrom directly held 333,469 shares of Vanda common stock. The trades were completed in multiple transactions at prices ranging from $8.085 to $8.81 per share.
Vanda Pharmaceuticals President and CEO Mihael Hristos Polymeropoulos reported an open-market sale of 156,235 shares of common stock at a weighted average price of $8.1734 per share. According to the disclosure, the shares were sold to satisfy tax obligations arising from the settlement of vested restricted stock units under RSU agreements.
After this transaction, the reporting person directly owned 2,704,496 shares of Vanda Pharmaceuticals common stock.
Vanda Pharmaceuticals Inc. senior vice president of business development Gunther Birznieks reported an open-market sale of 42,431 shares of common stock on March 2, 2026 at a weighted average price of $8.2659 per share. The shares were sold to satisfy tax obligations tied to the settlement of vested RSUs. After these transactions, he directly holds 494,197 shares. The sales occurred in multiple trades priced between $8.085 and $8.81 per share.